




PHARMACEUTICAL 2021

Aquestive Therapeutics Inc.
Rank 348 of 402





RealRate

PHARMACEUTICAL 2021

Aquestive Therapeutics Inc. Rank 348 of 402



The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 28% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 144% points.

The company's Economic Capital Ratio, given in the ranking table, is -160%, being 207% points below the market average of 47%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 44,625 |
| Cost of Goods Sold | 12,964 |
| Intangible Assets | 102 |
| Liabilities, Current | 21,104 |
| Liabilities, Non-Current | 8,424 |
| Other Assets | 11,284 |
| Other Compr. Net Income | 0 |
| Other Expenses | 13,022 |
| Other Liabilities | 81,853 |
| Other Net Income | 132 |
| Other Revenues | 45,849 |
| Property and Equipment | 6,873 |
| Research and Development | 19,886 |
| Selling, General and Administrative Expense | 55,892 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 62,884 |
| Liabilities | 111,381 |
| Expenses | 101,764 |
| Revenues | 45,849 |
| Stockholders Equity | -48,497 |
| Net Income | -55,783 |
| Comprehensive Net Income | -55,783 |
| Economic Capital Ratio | -160% |